| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2002; 41: 767-774
© 2002 British Society for Rheumatology
Original Papers |
Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study
Department of Epidemiology and Public Health, University of Leicester, Leicester,
1 School of Health Policy and Practice, University of East Anglia, Norwich,
2 ARC Epidemiology Unit, University of Manchester, Manchester and
3 Norfolk Arthritis Register, St Michael's Hospital, Aylsham, UK
Objective. To estimate the health service, non-health service and total costs and predictors of costs in individuals with early inflammatory polyarthritis (IP).
Methods. We conducted a prospective longitudinal study over a 6-month period. The participants were a random sample of 133 individuals who had enrolled with the community-based Norfolk Arthritis Register (NOAR) database between 1994 and 1999. The main outcome measures were the mean (per person) 6-month health service cost, non-health-service cost and total cost associated with IP.
Results. One hundred and fifteen of the 133 individuals who were recruited into the study completed 6 months of follow-up. The mean 6-month total cost was estimated to be £2800 per person, of which 14% was health service costs and the remainder non-health-service costs. Higher total costs were associated with lower health status and rheumatoid factor positivity.
Conclusions. Early IP has a considerable impact on both the health-care system and, more importantly, society. Non-health-service costs (i.e. costs incurred by the individual with the disease, their family and friends) account for a substantial proportion (86%) of the total costs associated with early IP.
KEY WORDS: Inflammatory polyarthritis, Cost of illness, Economics, Health-care costs, Non-health-care costs, Costs.
Correspondence to: N. Cooper, Department of Epidemiology and Public Health, University of Leicester, 22–28 Princess Road West, Leicester LE1 6TP, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J L Hulsemann, T Mittendorf, S Merkesdal, S Zeh, S Handelmann, J- M von der Schulenburg, H Zeidler, and J Ruof Direct costs related to rheumatoid arthritis: the patient perspective Ann Rheum Dis, October 1, 2005; 64(10): 1456 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Richardson, L Shepstone, F Poland, M Mugford, B Finlayson, and N Clemence Randomised controlled trial and cost consequences study comparing initial physiotherapy assessment and management with routine practice for selected patients in an accident and emergency department of an acute hospital Emerg. Med. J., February 1, 2005; 22(2): 87 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hallert, M. Husberg, D. Jonsson, and T. Skogh Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project) Rheumatology, November 1, 2004; 43(11): 1374 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Minden, M Niewerth, J Listing, T Biedermann, M Schontube, and A Zink Burden and cost of illness in patients with juvenile idiopathic arthritis Ann Rheum Dis, July 1, 2004; 63(7): 836 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Cooper, A. J. Sutton, M. Mugford, and K. R. Abrams Use of Bayesian Markov Chain Monte Carlo Methods to Model Cost-of-Illness Data Med Decis Making, January 1, 2003; 23(1): 38 - 53. [Abstract] [PDF]
|
|